About Inositec
Inositec is a company based in Zurich (Switzerland) founded in 2015 was acquired by Vifor Pharma Benelux in November 2021.. Inositec has raised $1.42 million across 3 funding rounds from investors including Zurcher Kantonalbank, CSL Vifor and VIP Partners. Inositec operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Koya Medical, Cempra and Bugworks Research, among others.
- Headquarter Zurich, Switzerland
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.42 M (USD)
in 3 rounds
-
Latest Funding Round
$1.42 M (USD), Seed
Oct 27, 2016
-
Investors
Zurcher Kantonalbank
& 3 more
-
Employee Count
Employee Count
-
Acquired by
Vifor Pharma Benelux
(Nov 22, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Inositec
Inositec has successfully raised a total of $1.42M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $1.42 million completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Seed — $1.4M
- First Round First Round
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2016 | Amount | Seed - Inositec | Valuation |
investors |
|
| Sep, 2016 | Amount | Debt – Conventional - Inositec | Valuation |
investors |
|
| Jun, 2015 | Amount | Seed - Inositec | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inositec
Inositec has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, CSL Vifor and VIP Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital is invested in US and Europe.
|
Founded Year | Domain | Location | |
|
Commercial banking services are provided across Switzerland by Zurcher Kantonalbank.
|
Founded Year | Domain | Location | |
|
Swiss startups are supported through innovative programs by Venturelab.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inositec
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Inositec
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inositec Comparisons
Competitors of Inositec
Inositec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Koya Medical, Cempra and Bugworks Research, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Provider of smart wearable compression technology for lymphedema and venous diseases
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inositec
Frequently Asked Questions about Inositec
When was Inositec founded?
Inositec was founded in 2015.
Where is Inositec located?
Inositec is headquartered in Zurich, Switzerland.
Is Inositec a funded company?
Inositec is a funded company, having raised a total of $1.42M across 3 funding rounds to date.
What does Inositec do?
Inositec was founded in 2015 in Zurich, Switzerland, with operations centered in the biotechnology sector. Therapeutics addressing soft tissue calcification disorders are developed, including INS-5010 as a non-antibiotic treatment for Clostridium difficile-related colon infections. INS-3001, an inhibitor of cardiovascular calcification, is also in development for aortic valve stenosis. The companys efforts target unmet needs in infectious and cardiovascular conditions.
Who are the top competitors of Inositec?
Inositec's top competitors include Spero Therapeutics, Koya Medical and Vedanta Biosciences.
Who are Inositec's investors?
Inositec has 4 investors. Key investors include Zurcher Kantonalbank, CSL Vifor, VIP Partners, and Venturelab.